8 Aug 2024 • SGLT2 inhibitors, already known for their cardiorenal benefits, also significantly cut the risk of developing type 2 diabetes in heart failure patients, found new research.

• In a large analysis of nearly 485,000 HF patients, SGLT2is reduced the incidence of T2D by 29% overall, with an even greater reduction of 38% in those with prediabetes.
• Dapagliflozin was more effective than empagliflozin in preventing T2D, showing a 53% risk reduction compared to 19% with empagliflozin.

These findings highlight the expanded benefits of SGLT2 inhibitors, suggesting they could be key in diabetes prevention for those at high risk.

Source: DOM | Read full story